secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0001437749-24-035686
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity: Two stenoparib patients exceed 14 months; $18.5M cash; lab services revenue
--------------------------------------------------------------------------------

- Two advanced ovarian cancer patients on stenoparib Phase 2 trial beyond 14 months, a notable duration given heavy pretreatment.
- Cash balance of $18.5M as of Sept 30, 2024, sufficient to initiate registrational trial toward FDA approval.
- Allarity Medical Lab signs external service agreements for DRP and gene expression analysis with multiple biotech firms.
- Revenue from lab services reduces overall lab cost base and advances DRP platform in oncology field.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774924035686/0001437749-24-035686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774924035686/allr20241118_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-035686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer